Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sagimet Biosciences Inc.

8.69
-0.2000-2.25%
Pre-market: 8.61-0.0800-0.92%07:00 EDT
Volume:651.29K
Turnover:5.72M
Market Cap:279.78M
PE:-4.89
High:9.19
Open:8.82
Low:8.60
Close:8.89
Loading ...

Canaccord Genuity Initiates Coverage on Sagimet Biosciences With Buy Rating, $28 Price Target

MT Newswires Live
·
24 Jul

Sagimet Biosciences initiated with a Buy at Canaccord

TIPRANKS
·
24 Jul

Top Executives at Sagimet Biosciences Unload Significant Shares!

TIPRANKS
·
24 Jul

Chief Medical Officer Eduardo Bruno Martins Reports Disposal of Common Shares in Sagimet Biosciences Inc

Reuters
·
24 Jul

Sagimet Biosciences Elects New Directors at Annual Meeting

TIPRANKS
·
11 Jun

Sagimet Biosciences Inc. Announces Revised Executive Compensation Agreements with Enhanced Severance Provisions

Reuters
·
11 Jun

Sagimet Biosciences to host KOL event on denifanstat results

TIPRANKS
·
09 Jun

Sagimet Biosciences Announces Positive Phase 3 Trial Results for Denifanstat in Treating Moderate to Severe Acne

Reuters
·
09 Jun

Sagimet Biosciences Is Maintained at Buy by Jones Trading

Dow Jones
·
07 Jun

Promising Potential of Sagimet Biosciences: Buy Rating Affirmed by Positive Phase 3 Trial Results and Strategic Advancements

TIPRANKS
·
05 Jun

BUZZ-U.S. STOCKS ON THE MOVE-TransMedics, Centrus Energy,  MongoDB

Reuters
·
05 Jun

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires Live
·
04 Jun

Private Payrolls Rise Less Than Expected in May, Stifling US Equity Futures Pre-Bell

MT Newswires Live
·
04 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Trevi Therapeutics, Cactus, Copper miners

Reuters
·
04 Jun

Sagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment

Dow Jones
·
04 Jun

BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China

Reuters
·
04 Jun

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne

Reuters
·
04 Jun

Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Janux Therapeutics Inc (JANX)

TIPRANKS
·
03 Jun

Sagimet Biosciences price target lowered to $25 from $30 at Oppenheimer

TIPRANKS
·
13 May

Sagimet Biosciences Reports Q1 2025 Financial Results

TIPRANKS
·
10 May